Meral Beksac, MD, Ankara University, Ankara, Turkey, talks on the efficacy of trametinib in patients with triple-class refractory multiple myeloma who are KRAS or NRAS-mutated. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.